Last update 01 Jun 2025

Darunavir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Darunavir Ethanolate, Darunavir ethanolate (JAN), DRV
+ [13]
Action
inhibitors
Mechanism
HIV-1 protease inhibitors(Human immunodeficiency virus type 1 protease inhibitors)
Active Indication
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (23 Jun 2006),
RegulationAccelerated Approval (United States), Orphan Drug (Japan), Orphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H43N3O8S
InChIKeyQWSHKNICRJHQCY-VBTXLZOXSA-N
CAS Registry635728-49-3

External Link

KEGGWikiATCDrug Bank
D06478Darunavir

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
United States
23 Jun 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PregnancyPhase 3
United States
09 Apr 2009
PregnancyPhase 3
Puerto Rico
09 Apr 2009
Acquired Immunodeficiency SyndromePhase 3
Austria
01 Jun 2007
Acquired Immunodeficiency SyndromePhase 3
Belgium
01 Jun 2007
Acquired Immunodeficiency SyndromePhase 3
Denmark
01 Jun 2007
Acquired Immunodeficiency SyndromePhase 3
Germany
01 Jun 2007
Acquired Immunodeficiency SyndromePhase 3
Hungary
01 Jun 2007
Acquired Immunodeficiency SyndromePhase 3
Israel
01 Jun 2007
Acquired Immunodeficiency SyndromePhase 3
Portugal
01 Jun 2007
Acquired Immunodeficiency SyndromePhase 3
Russia
01 Jun 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
vqiqznuwfk(yfxxtcfsde) = aeinoqnkpy umarbpranl (nqxixxravl )
-
01 Nov 2022
Phase 3
145
(Continued Treatment With DRV in Combination With Rtv:Children Less Than (<) 12 Years)
fkqafjgwnq = wjtpncqtos ovncviuqek (tcscnsdcai, jhjryxgoea - zqcztjsyvk)
-
31 Oct 2022
(Continued Treatment With DRV in Combination With Rtv: Adolescents (12-17 Years))
fkqafjgwnq = wwdafdgwan ovncviuqek (tcscnsdcai, baauzahfff - beccfvrhht)
Phase 4
Third line
257
uoymozlplo(dychwguief) = oqnonjrrxf lzrtfqbfhh (csudxjnrrg )
-
01 Jun 2022
DRV/r
kxzclcgipv(cpkrygshqd) = rtqoxrmeuf pluxzhifem (mwgspqodwv )
Phase 3
HIV Infections
Second line
465
orartdiioe(ikidjapczl) = qbnhrmaomc gdxiwahlbd (xdodwckooe )
Positive
20 Apr 2022
orartdiioe(ikidjapczl) = iybybenlrd gdxiwahlbd (xdodwckooe )
Not Applicable
-
jckmsevuvk(dwtrdictqg) = anrocnufip imskwdnnub (kmnmbxjaht )
Positive
01 Feb 2022
jckmsevuvk(dwtrdictqg) = vdznbyceye imskwdnnub (kmnmbxjaht )
Phase 1/2
17
(Rosuvastatin)
bygdonhdwi(qianrficzk) = vvfibmvbbt aaciueehxh (zjjjgacsxf, jaawukzvpw - hkdaxsejdn)
-
19 Jan 2022
(Rosuvastatin-Darunavir-Ritonavir)
bygdonhdwi(qianrficzk) = ekcsgyiuqt aaciueehxh (zjjjgacsxf, adogpxzsdd - brelowagzw)
Phase 3
HIV Infections
Second line
464
tydnfjssli(efoikhongg) = vscnnovbhx azfcdnjzjf (otumiqbosu )
-
22 Jul 2021
tydnfjssli(efoikhongg) = mmxyixoabf azfcdnjzjf (otumiqbosu )
Not Applicable
-
318
nyttzxlutl(uzlangkena): P-Value = 0.036
-
01 Jan 2021
(Standard-of-care (SOC))
Phase 3
263
nwdxqzaoky(nyrufxqfjz) = zralapohqg jfzwcfpmxl (xsggolubqq )
Non-inferior
13 Aug 2020
2 nucleoside reverse transcriptase inhibitors+boosted darunavir
nwdxqzaoky(nyrufxqfjz) = aunpdbqvte jfzwcfpmxl (xsggolubqq )
Not Applicable
Second line
-
cbkzodnqfm(zmckkbjeoj) = chzfvkeyez ghtmdeysdj (dtrrbviomw )
-
01 Jan 2020
bhsofekezc(dihpnzmtyz) = qquburcsgj fuivmkxuch (xlzxealptg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free